Preoperative u-PAR Gene Expression in Bone Marrow Indicates the Potential Power of Recurrence in Breast Cancer Cases

  • Koshi Mimori
  • Akemi Kataoka
  • Hiroshi Yamaguchi
  • Norikazu Masuda
  • Yoshimasa Kosaka
  • Hideshi Ishii
  • Shinji Ohno
  • Masaki Mori
Translational Research and Biomarkers

ABSTRACT

Introduction

The clinical significance of isolated tumor cells (ITC) in peripheral blood (PB) and bone marrow (BM) as predictive markers in the recurrence or metastasis of breast cancer has not yet been determined. In the current study, we focused on the urokinase plasminogen activator receptor (u-PAR) gene as a powerful indicator of the potential to relapse after surgery.

Patients and Methods

We examined CK-7 and CK19 as an ITC marker and u-PAR as a candidate indicator for metastasis in PB and BM from 800 cases of breast cancer by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR). Serum tumor markers, carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3), were compared with u-PAR or CK status.

Results

CK7 in PB was positive in 262 cases that showed a poorer disease-free survival (DFS) than 478 CK7(–) cases (P < 0.05). The 153 cases of u-PAR(+) in BM showed significantly poorer DFS and overall survival (OS) than did the 579 cases of u-PAR(–) in BM (P < 0001 and P < 0.0001, respectively). In PB, a significant difference was also observed between 330 cases of u-PAR(+) and 437 cases of u-PAR(–) (P < 0.0001). The hazard ratio (HR) for prediction of recurrence was significantly higher in u-PAR (P < 0.0001; HR 0.0519) than the level of three serum tumor markers.

Discussion

u-PAR expresses in cancer cells during the dormant phase. The current findings revealed that the expression levels of u-PAR in PB and BM evaluated preoperatively indicate the potential to relapse or metastasize after surgery.

Keywords

Overall Survival Breast Cancer Case Isolate Tumor Cell Serum Tumor Marker Disseminate Tumor Cell 

Notes

Acknowledgement

This work was supported by the following grant sponsors: CREST, Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, grant numbers 17109013, 17591411, 17591413, 18390367, 18590333, 18659384, and 18790964; The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Grant-in-Aid for Scientific Research on Priority Areas, grant number 18015039; and the Third Term Comprehensive Ten-Year Strategy for Cancer Control, grant number 16271201.

References

  1. 1.
    Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001;19:1468–75.PubMedGoogle Scholar
  2. 2.
    Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New Eng J Med. 2000;342:525–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354:197–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients. Clin Cancer Res. 2000;6:4176–85.PubMedGoogle Scholar
  5. 5.
    Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat. 1997;45:241–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Salvadori B, Squicciarini P, Rovini D, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 1990;26:865–7.PubMedGoogle Scholar
  7. 7.
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. New Eng J Med. 2005;353:793–802.PubMedCrossRefGoogle Scholar
  8. 8.
    Masuda TA, Kataoka A, Ohno S, et al. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol. 2005;26:721–30.PubMedGoogle Scholar
  9. 9.
    Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995;1:1035–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006;26:87–98.PubMedGoogle Scholar
  11. 11.
    Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res. 2007;9:208.PubMedCrossRefGoogle Scholar
  12. 12.
    Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol. 2007;4:699–710.PubMedCrossRefGoogle Scholar
  13. 13.
    Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle. Georgetown, Tex 2006;5:1760–71.Google Scholar
  14. 14.
    Iinuma H, Okinaga K, Egami H, et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006;28:297–306.PubMedGoogle Scholar
  15. 15.
    Holmgren L, O’Reilly M, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Murray C. Tumour dormancy: not so sleepy after all. Nat Med. 1995;1:117–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Pantel K, Brakenhoff R Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Uhr J, Scheuermann R, Street N, Vitetta E. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med. 1997;3:505–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Oncol. 2008;123:1991–2006.Google Scholar
  20. 20.
    Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. Apmis. 2008;116:754–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Allgayer H, Aguirre-Ghiso JA. The urokinase receptor (u-PAR)–a link between tumor cell dormancy and minimal residual disease in bone marrow? Apmis. 2008;116:602–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Mimori K, Fukagawa T, Kosaka Y, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 2008;14:2609–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 1998;110:27–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Schlimok G, Funke I, Pantel K, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer. 1991;27:1461–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol. 2000;190:190–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993;53:1911–5.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Koshi Mimori
    • 1
  • Akemi Kataoka
    • 1
  • Hiroshi Yamaguchi
    • 2
  • Norikazu Masuda
    • 3
  • Yoshimasa Kosaka
    • 1
  • Hideshi Ishii
    • 1
  • Shinji Ohno
    • 2
  • Masaki Mori
    • 1
  1. 1.Department of Surgical Oncology, Medical Institute of BioregulationKyushu UniversityBeppuJapan
  2. 2.Department of Breast OncologyKyushu Cancer CenterFukuokaJapan
  3. 3.Osaka National HospitalOsakaJapan

Personalised recommendations